Can a common antihistamine boost multiple sclerosis treatment?
Disease control
Recruiting now
Researchers are testing whether adding terfenadine to standard first-line disease-modifying therapy is safe and may improve outcomes for adults with relapsing-remitting multiple sclerosis. About 100 participants aged 18 to 65 will be randomly assigned to receive either terfenadin…
Phase 2 • Sponsor: Chuan Qin • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC